Table 2

Comparison of investigative parameters among patients in each group

Investigations

Group 1

PAH

Group 2

At Risk

Group 3

ILD

Group 4

Controls

P value

TTE parameters

TRV (m/s)

3.8 ± 0.7

2.95 ± 0.3

2.54 ± 0.4

2.20 ± 0.2

< 0.0001

sPAP (mm Hg)

65.8 ± 27.3

43.8 ± 7.2

32.1 ± 5.3

26.3 ± 2.6

< 0.0001

RHC results

mPAP (mm Hg)

40.2 ± 12.5

N/A

N/A

N/A

N/A

mRAP (mm Hg)

10.1 ± 3.3

N/A

N/A

N/A

N/A

PVR (Wood units)

6.2 ± 3.4

N/A

N/A

N/A

N/A

PFT

FVC (% pred)

75.5 ± 23.4

100.6 ± 19.5

68.7 ± 13.2

102.8 ± 13.4

< 0.0001^a

DLCO_corr (% pred)

45.6 ± 11.7

61.0 ± 15.1

48.0 ± 12.7

86.8 ± 13.0

< 0.0001^b

FVC/DLCO_corr

1.76 ± 0.38

1.73 ± 0.46

1.46 ± 0.31

1.20 ± 0.20

< 0.0001^c

6MWD (m)

337 ± 100

N/A

458 ± 84

N/A

N/A

Log NT-proBNP

6.72 ± 1.48

5.18 ± 1.11

4.72 ± 0.57

4.12 ± 0.63

< 0.0001

NT-proBNP (pg/ml)

1818 ± 2367

278 ± 243

133 ± 87

72 ± 38

< 0.0001^d

6MWD, 6-minute walk distance; DLCO, diffusion capacity of lung for carbon monoxide (% predicted); FVC, forced vital capacity (% predicted); ILD, interstitial lung disease; mPAP, mean pulmonary artery pressure; mRAP, mean right atrial pressure; NT-proBNP, N-terminal pro brain natriuretic peptide; PAH, pulmonary arterial hypertension; PVR, pulmonary vascular resistance; sPAP, systolic pulmonary artery pressure; TRV, tricuspid regurgitant velocity. ^aLower FVC in PAH and ILD groups, versus "at risk" and controls

^bLower DLCO in PAH and ILD groups, versus "at risk" and controls. ^cHigher FVC/DLCO in PAH and "at risk" groups, versus ILD and controls. ^dHigher NT-ProBNP in PAH versus other groups, and "at risk" versus controls.

Thakkar et al. Arthritis Research & Therapy 2012 14:R143   doi:10.1186/ar3876